QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: Writing the Changes to Reference Safety Information Section in a PBRER

Test your understanding of the concepts covered by Writing the Changes to Reference Safety Information Section in a PBRER.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which scenario most clearly requires a concise explanation of regional implementation differences in the PBRER?

Different countries used different page layouts for the same label A regional difference changes how a major risk or benefit-risk conclusion is interpreted All countries implemented the same update on the same date A partner changed its internal document numbering system

Question 2 of 10 A new contraindication applies only to an oncology indication of a product also authorised for other indications. How should the change be described?

As a contraindication applying universally to all uses As a change affecting the specific oncology indication and relevant population As an editorial update because it does not affect every indication As a class-wide change for all products with the same active substance

Question 3 of 10 Which change would normally warrant substantive discussion in the RSI section?

Correction of a typographical error with no scientific impact Reformatting of a table without changing its content Addition of an important potential risk Standardisation of punctuation across sections

Question 4 of 10 The CCSI was revised in January, an EU label was implemented in March, and approval in the United States occurred in June. What should the RSI section primarily do?

List every national implementation date in equal detail Identify the applicable RSI at the data lock point and summarise important scientific changes Treat the CCSI revision as ineffective until every country has implemented it Use the most recently approved national label as the global RSI

Question 5 of 10 A biosimilar's safety information is being aligned with that of the reference product, but implementation dates differ between jurisdictions. What is the most appropriate interpretation?

The timing difference automatically demonstrates different scientific conclusions The difference should be described objectively if relevant, while focusing on the RSI applicable to the product under review The biosimilar must use the reference product's national label regardless of local approval The difference should be omitted because related products cannot be discussed in a PBRER

Question 6 of 10 Why should important RSI changes be linked to later PBRER sections?

To ensure the same wording is copied throughout the report To demonstrate that the revised recognised safety profile was considered in signal, risk, and benefit-risk evaluations To reduce the need for supporting evidence in signal evaluation To replace the need for risk characterisation

Question 7 of 10 What is the most appropriate level of detail for the supporting evidence behind an important RSI change?

All evidence should be reproduced in the RSI section Only the change should be identified; no explanation is ever needed The RSI section should summarise the change and significance, while detailed evidence belongs in the relevant evaluation sections Evidence should be presented only as a history of national submissions

Question 8 of 10 A new adverse reaction was added to the CCSI during the interval. Which downstream action is most appropriate?

Ignore it in the PBRER because it is already listed in the RSI Consider whether it should inform signal evaluation and other relevant safety discussions Remove related cases from the cumulative data set Discuss it only in the regulatory submission history

Question 9 of 10 A licensing agreement allows partners to adapt product information regionally rather than requiring immediate harmonised implementation. What should the PBRER author do first?

Assume that the partner's local label is the RSI for the entire PBRER Determine which RSI was agreed as the basis of the PBRER and identify differences relevant to interpretation Include all contractual terms in the PBRER Exclude all partner information because it is commercially confidential

Question 10 of 10 Which statement best distinguishes global RSI from regional product information?

They are interchangeable whenever a product is marketed internationally Regional product information always has priority over the global scientific reference The global RSI expresses the core scientific safety position, while regional information reflects local regulatory implementation The global RSI is used only for commercial planning and not for aggregate safety evaluation

QPPV.com

Knowledge Assessment: Writing the Changes to Reference Safety Information Section in a PBRER

Cookie Settings